Smead Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,397,536
| Closed | -$46.4M | – | 34 |
|
|
2023
Q3 | $46.4M | Sell |
1,397,536
-44,911
| -3% | -$1.59M | 0.95% | 24 |
|
|
2023
Q2 | $52.9M | Sell |
1,442,447
-21,992
| -2% | -$856K | 1.05% | 24 |
|
|
2023
Q1 | $59.7M | Buy |
1,464,439
+39,234
| +3% | +$1.69M | 1.19% | 24 |
|
|
2022
Q4 | $73M | Buy |
1,425,205
+122,577
| +9% | +$5.88M | 1.56% | 22 |
|
|
2022
Q3 | $57M | Buy |
1,302,628
+20,618
| +2% | +$1M | 1.48% | 22 |
|
|
2022
Q2 | $67.2M | Buy |
1,282,010
+73,062
| +6% | +$3.72M | 1.72% | 22 |
|
|
2022
Q1 | $62.6M | Sell |
1,208,948
-593,221
| -33% | -$30.8M | 1.45% | 22 |
|
|
2021
Q4 | $106M | Buy |
1,802,169
+317,497
| +21% | +$15.7M | 2.77% | 18 |
|
|
2021
Q3 | $63.9M | Buy |
1,484,672
+46,804
| +3% | +$2.07M | 2.18% | 22 |
|
|
2021
Q2 | $56.3M | Buy |
1,437,868
+178,965
| +14% | +$6.96M | 1.97% | 22 |
|
|
2021
Q1 | $45.6M | Buy |
1,258,903
+99,969
| +9% | +$3.55M | 2.01% | 22 |
|
|
2020
Q4 | $42.7M | Sell |
1,158,934
-116,490
| -9% | -$4.27M | 2.47% | 22 |
|
|
2020
Q3 | $44.4M | Sell |
1,275,424
-136,886
| -10% | -$4.8M | 2.81% | 17 |
|
|
2020
Q2 | $43.8M | Sell |
1,412,310
-125,185
| -8% | -$4.25M | 2.76% | 19 |
|
|
2020
Q1 | $47.6M | Sell |
1,537,495
-85,180
| -5% | -$2.9M | 3.38% | 17 |
|
|
2019
Q4 | $60.3M | Buy |
1,622,675
+27,049
| +2% | +$963K | 2.68% | 21 |
|
|
2019
Q3 | $54.4M | Sell |
1,595,626
-45,932
| -3% | -$1.67M | 2.66% | 22 |
|
|
2019
Q2 | $67.5M | Sell |
1,641,558
-52,928
| -3% | -$2.1M | 3.25% | 16 |
|
|
2019
Q1 | $68.3M | Sell |
1,694,486
-55,610
| -3% | -$2.23M | 3.47% | 16 |
|
|
2018
Q4 | $72.5M | Sell |
1,750,096
-85,250
| -5% | -$3.54M | 3.79% | 14 |
|
|
2018
Q3 | $76.7M | Sell |
1,835,346
-47,544
| -3% | -$1.83M | 3.47% | 14 |
|
|
2018
Q2 | $64.8M | Sell |
1,882,890
-34,042
| -2% | -$1.16M | 3.09% | 17 |
|
|
2018
Q1 | $64.5M | Sell |
1,916,932
-3,169
| -0.2% | -$109K | 3.13% | 17 |
|
|
2017
Q4 | $66M | Sell |
1,920,101
-87,821
| -4% | -$2.99M | 3.01% | 18 |
|
|
2017
Q3 | $68M | Sell |
2,007,922
-27,307
| -1% | -$878K | 3.24% | 16 |
|
|
2017
Q2 | $64.9M | Sell |
2,035,229
-47,964
| -2% | -$1.51M | 3.13% | 16 |
|
|
2017
Q1 | $67.6M | Sell |
2,083,193
-34,026
| -2% | -$1.07M | 3.41% | 15 |
|
|
2016
Q4 | $65.2M | Sell |
2,117,219
-282,549
| -12% | -$8.63M | 3.31% | 16 |
|
|
2016
Q3 | $77.1M | Sell |
2,399,768
-148,665
| -6% | -$4.97M | 3.67% | 13 |
|
|
2016
Q2 | $85.1M | Sell |
2,548,433
-156,580
| -6% | -$5M | 4% | 12 |
|
|
2016
Q1 | $76.1M | Sell |
2,705,013
-260,883
| -9% | -$7.45M | 3.29% | 17 |
|
|
2015
Q4 | $75.3M | Buy |
2,965,896
+783,616
| +36% | +$24.7M | 3.36% | 17 |
|
|
2015
Q3 | $65M | Buy |
2,182,280
+498,611
| +30% | +$16M | 3.47% | 17 |
|
|
2015
Q2 | $53.6M | Buy |
1,683,669
+178,588
| +12% | +$5.82M | 3.5% | 15 |
|
|
2015
Q1 | $49.7M | Buy |
1,505,081
+242,024
| +19% | +$7.69M | 3.66% | 13 |
|
|
2014
Q4 | $37.3M | Buy |
1,263,057
+282,614
| +29% | +$8.1M | 3.44% | 16 |
|
|
2014
Q3 | $27.5M | Buy |
980,443
+29,211
| +3% | +$820K | 2.97% | 19 |
|
|
2014
Q2 | $26.8M | Buy |
951,232
+43,909
| +5% | +$1.25M | 2.92% | 17 |
|
|
2014
Q1 | $27.6M | Buy |
907,323
+112,502
| +14% | +$3.35M | 3.33% | 16 |
|
|
2013
Q4 | $23.1M | Buy |
794,821
+63,376
| +9% | +$1.84M | 3.18% | 16 |
|
|
2013
Q3 | $19.9M | Buy |
731,445
+114,515
| +19% | +$3.12M | 3.23% | 17 |
|
|
2013
Q2 | $16.4M | Buy |
+616,930
| New | +$17M | 3.32% | 16 |
|
Other funds holding PFE
Smead Capital Management's PFE Position: Q4 2023 in Review
Smead Capital Management sold out of Pfizer (PFE) in Q4 2023, closing a stake of 1,397,536 shares — an estimated $46.4M sold.
Smead Capital Management first reported a position in PFE in Q2 2013 and held it in 42 quarters. The position peaked at $106M in Q4 2021. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.
- Smead Capital Management reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
- Smead Capital Management sold 1,397,536 Pfizer shares in Q4 2023, an estimated $46.4M.
- Smead Capital Management first reported a position in Pfizer in Q2 2013 and held it in 42 quarters.
- Smead Capital Management's Pfizer position peaked at $106M in Q4 2021.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.
Based on Smead Capital Management's 13F filing for Q4 2023, filed 31 Jan 2024.